Healthcare provider profile · identity verified

Brian J Rush, MD

Family Practice · PARK CITY, UT · NPI 1184672511

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	325	117
Atorvastatin Calcium	Atorvastatin Calcium	300	100
Lisinopril	Lisinopril	168	62
Losartan Potassium	Losartan Potassium	154	58
Metformin Hcl Er	Metformin Hcl	130	48
Levothyroxine Sodium	Levothyroxine Sodium	113	44
Tamsulosin Hcl	Tamsulosin Hcl	100	33
Allopurinol	Allopurinol	80	27
Trazodone Hcl	Trazodone Hcl	79	26
Gabapentin	Gabapentin	71	28
Hydrochlorothiazide	Hydrochlorothiazide	68	19
Metoprolol Succinate	Metoprolol Succinate	67	26
Amlodipine Besylate	Amlodipine Besylate	65	26
Omeprazole	Omeprazole	61	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	19
Metformin Hcl	Metformin Hcl	59	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	58	20
Finasteride	Finasteride	56	20
Eliquis	Apixaban	54	19
Zolpidem Tartrate	Zolpidem Tartrate	48	23
Diazepam	Diazepam	47	11
Alendronate Sodium	Alendronate Sodium	41	16
Valacyclovir	Valacyclovir Hcl	39	17
Celecoxib	Celecoxib	36	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	34	15
Montelukast Sodium	Montelukast Sodium	34	11
Doxepin Hcl	Doxepin Hcl	33	11
Fluticasone Propionate	Fluticasone Propionate	32	14
Alprazolam	Alprazolam	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	31	13
Clonazepam	Clonazepam	27	suppressed
Symbicort	Budesonide/Formoterol Fumarate	27	13
Progesterone	Progesterone, Micronized	26	suppressed
Prednisone	Prednisone	25	suppressed
Lorazepam	Lorazepam	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Sertraline Hcl	Sertraline Hcl	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	22	suppressed
Morphine Sulfate Er	Morphine Sulfate	22	suppressed
Testosterone Cypionate	Testosterone Cypionate	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	11
Mounjaro	Tirzepatide	21	suppressed
Acyclovir	Acyclovir	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Liothyronine Sodium	Liothyronine Sodium	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Colchicine	Colchicine	17	suppressed
Estradiol	Estradiol	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Temazepam	Temazepam	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Glipizide Er	Glipizide	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Meloxicam	Meloxicam	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	12	suppressed
Ozempic	Semaglutide	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error